This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen acción LCIN.Q
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Lannett Company, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$3.72 |
| 52 Week Low | US$0.01 |
| Beta | 0.94 |
| 1 Month Change | 48.25% |
| 3 Month Change | -98.21% |
| 1 Year Change | -98.68% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.41% |
Noticias y actualizaciones recientes
Recent updates
Lannett announces 1-for-4 reverse stock split
Jan 25Lannett gains on patent deal for biosimilar insulin device
Nov 07Lannett gets FDA approval to manufacture Numbrino® at Seymour plant
Oct 21Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's Estimates
Sep 01
Lannett GAAP EPS of -$2.30, revenue of $74.19M
Aug 24Lannett: A Self-Inflicted Crisis
Feb 22Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts
Feb 05A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)
Nov 05Is Lannett Company (NYSE:LCI) A Risky Investment?
Jun 20Lannett down 5.5%, SVC gains 5.7% as S&P 500 makes room for Organon
May 27Is Lannett Company (NYSE:LCI) A Risky Investment?
Mar 18Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)
Feb 11
Lannett shares slide on 2021 forecast cut, QF2 topline fall
Feb 04What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 15Is Lannett Company (NYSE:LCI) Using Too Much Debt?
Dec 11Lannett pays off remaining $42M in outstanding loans
Nov 30Lannett launches authorized generic of Tirosint
Nov 03Rentabilidad de los accionistas
| LCIN.Q | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 12.7% | -3.1% | -1.7% |
| 1Y | -98.7% | 11.5% | 22.4% |
Rentabilidad vs. Industria: LCIN.Q underperformed the US Pharmaceuticals industry which returned 4% over the past year.
Rentabilidad vs. Mercado: LCIN.Q underperformed the US Market which returned 14.5% over the past year.
Volatilidad de los precios
| LCIN.Q volatility | |
|---|---|
| LCIN.Q Average Weekly Movement | 50.7% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: LCIN.Q's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: LCIN.Q's weekly volatility has increased from 28% to 51% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1942 | 564 | Tim Crew | www.lannett.com |
Resumen de fundamentos de Lannett Company, Inc.
| Estadísticas fundamentales de LCIN.Q | |
|---|---|
| Capitalización bursátil | US$319.24k |
| Beneficios(TTM) | -US$259.09m |
| Ingresos (TTM) | US$310.67m |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está LCIN.Q sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LCIN.Q | |
|---|---|
| Ingresos | US$310.67m |
| Coste de los ingresos | US$254.66m |
| Beneficio bruto | US$56.01m |
| Otros gastos | US$315.10m |
| Beneficios | -US$259.09m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -24.06 |
| Margen bruto | 18.03% |
| Margen de beneficio neto | -83.40% |
| Ratio deuda/patrimonio | -152.4% |
¿Cómo se ha desempeñado LCIN.Q a largo plazo?
Ver rendimiento histórico y comparativa